Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front‐line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin,megakaryocyte potentiating factor,and cancer antigen 125期刊界 All Journals 搜尽天下杂志传播学术成果专业期刊搜索期刊信息化学术搜索

Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front‐line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin,megakaryocyte potentiating factor,and cancer antigen 125

Authors:	Raffit Hassan MD Elad Sharon MD Anish Thomas MD Jingli Zhang BS Alexander Ling MD Markku Miettinen MD Robert J. Kreitman MD Seth M. Steinberg PhD Kevin Hollevoet PhD Ira Pastan MD

Affiliation:	1. Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland;2. Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, Maryland;3. Radiology and Imaging Sciences, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland;4. Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland;5. Biostatistics and Data Management Section, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland

Abstract:

Keywords:	mesothelin pleural mesothelioma SS1P immunotoxin